Compare IXHL & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | PETS |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Retail-Drug Stores and Proprietary Stores |
| Sector | | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 63.7M |
| IPO Year | N/A | N/A |
| Metric | IXHL | PETS |
|---|---|---|
| Price | $0.41 | $3.91 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | ★ 24.9M | 6.9M |
| Earning Date | 11-14-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,000.00 | ★ $226,972,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $1.57 |
| 52 Week High | $2.25 | $6.08 |
| Indicator | IXHL | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 80.75 |
| Support Level | $0.38 | $1.69 |
| Resistance Level | $0.45 | $4.05 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 47.53 | 92.49 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.